8 August 2025
Scancell Holdings plc
("Scancell" or the "Company")
Director Dealing
Scancell Holdings plc (AIM: SCLP), the developer of Immunobody® and Moditope® active immunotherapies to treat cancer, announces that Vulpes Testudo Fund, a fund closely associated with Martin Diggle, Non-Executive Director, has purchased 102,236 ordinary shares of 0.1p each ('Ordinary Shares') in the Company on 7 August 2025 at a price of 10.85 pence per share. Following the purchase, Vulpes Life Science Fund and Vulpes Testudo Fund together hold 140,387,037 ordinary shares representing 13.53% of the company.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
| 1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
| a) |
Name |
Vulpes Testudo Fund |
| 2 |
Reason for the notification |
|
| a) |
Position/status |
Fund closely associated with Martin Diggle, Non-Executive Director |
| b) |
Initial notification/Amendment |
Initial notification |
| 3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
| a) |
Name |
Scancell Holdings plc |
| b) |
LEI |
2138008RXEG856SNP666 |
| 4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
| a) |
Description of the financial instrument, type of instrument |
Ordinary Shares of 0.1 pence each |
| b) |
Identification Code |
GB00B63D3314 |
| c) |
Nature of the transaction |
Purchase of Ordinary Shares |
| |
|
|
| d) |
Price(s) and volume(s) |
10.85 pence and 102,236 |
| e) |
Aggregated information - Aggregated volume - Price |
102,236 Ordinary Shares 10.85 pence per Ordinary Share |
| f) |
Date of the transaction (s) |
7 August 2025 |
| g) |
Place of the transaction |
London Stock Exchange, AIM |
-ENDS-
Scancell (LSE:SCLP; www.scancell.co.uk ) is a clinical stage biotechnology company developing targeted off-the-shelf active immunotherapies, to generate safe and long-lasting tumor-specific immunity for a cancer-free future. iSCIB1/ iSCIB1+, the lead product from their DNA Immunobody® platform has demonstrated safe, durable and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma . Modi-1, the lead peptide immunotherapy from their Moditope ® platform, is being investigated in a Phase 2 study in a broad range of solid tumors. In addition, Scancell's wholly-owned subsidiary, Glymab Therapeutics Ltd., is developing an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumor specific glycans, two of which already have been licensed and are being developed by Genmab A/S, an international biotechnology company and global leader in the antibody therapeutics space.
For more information please contact:
| |
|
| Scancell Holdings plc |
+44 (0) 20 3709 5700 |
| Phil L'Huillier, CEO |
|
| Sath Nirmalananthan, CFO |
|
| |
|
| Panmure Liberum (Nominated Adviser and Joint Broker) |
+44 (0) 20 7886 2500 |
| Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking) |
|
| |
|
| WG Partners LLP (Joint Broker) David Wilson, Claes Spang |
+44 (0) 20 3705 9330
|
| |
|
| Investor and media relations Mary-Ann Chang |
+44 (0) 20 7483 284853 MaryAnnChang@scancell.co.uk |
| |
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.